tuneTypical Dose
Many studies used 10 to 20 mg daily, with some independent trials testing much higher doses without benefit
Natural Compound
Policosanol
Policosanol
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Trials generally looked for lipid changes over 8 to 12 weeks and independent studies remained negative.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Policosanol is not a dependable lipid-lowering supplement, because the strongest independent trials failed to reproduce the dramatic cholesterol effects reported in older Cuban studies.
Policosanol is a good example of why supplement evidence needs source-context, not just pooled averages. Early Cuban trials reported striking LDL reductions that made policosanol look almost statin-like. Later independent randomized trials did not reproduce those effects. That leaves the overall evidence conflicted, with the most credibility going to the negative independent studies rather than to the older concentrated positive literature.
Policosanol is usually marketed as a long-chain alcohol mixture that modulates cholesterol synthesis or lipoprotein metabolism. Whatever the mechanism may be, the better independent human trials do not show dependable lipid-lowering efficacy.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- No dependable LDL-lowering effect in independent randomized trials
Secondary Outcomes
- Conflicted literature because older Cuban studies were strongly positive
- Better framed as poor-replication evidence than as true statin-like efficacy
Safety
Contraindications and Interactions
Contraindications
- Using it instead of proven LDL-lowering therapy
Side effects
- Mild GI discomfort
Interactions
No entries provided
Avoid if
- You are expecting statin-like LDL lowering
- You have elevated cardiovascular risk and need proven therapy
Evidence
Study-level References
po-SRC-001Randomized controlled trial
Sourceopen_in_newBerthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262-2269. doi:10.1001/jama.295.19.2262. PMID:16705107.
Population: Adults with hypercholesterolemia or combined hyperlipidemia.
Dose protocol: 10 to 80 mg daily over 12 weeks
Key findings: No meaningful lipid-lowering effect at any tested dose.
Notes: Most important independent negative replication trial.
Paper content
This is the most important independent reality-check trial for policosanol. Despite testing multiple doses up to 80 mg daily, the study found no lipid-lowering effect beyond placebo, while the atorvastatin comparator worked as expected. That sharply undermines broad claims that policosanol behaves like a natural statin.
po-SRC-002Randomized controlled trial
Sourceopen_in_newCubeddu LX, Cubeddu RJ, Heimowitz T, et al. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr. 2006;84(6):1543-1548. doi:10.3945/ajcn.106.117606. PMID:17158441.
Population: Healthy adults with mild hypercholesterolemia.
Dose protocol: 20 mg daily for 8 weeks
Key findings: No improvement in LDL cholesterol, total cholesterol, HDL cholesterol, or triglycerides.
Notes: Confirms the independent negative-replication pattern.
Paper content
This second independent negative trial is important because it again failed to show meaningful LDL or total-cholesterol improvement. Together with the JAMA trial, it makes the positive early literature look heavily dependent on specific investigators or formulations.
po-SRC-003Systematic review and meta-analysis
Sourceopen_in_newGong Y, Qin X, Yuan F, Hu M, Peng J, Li Y. Efficacy and safety of sugarcane policosanol on dyslipidemia: a meta-analysis of randomized controlled trials. Hypertens Res. 2018;41(3):193-202. doi:10.1038/hr.2017.64. PMID:28730734.
Population: Adults with dyslipidemia enrolled in randomized controlled trials of sugarcane policosanol.
Dose protocol: Trial specific across 22 randomized studies
Key findings: Positive pooled lipid effects, but with heavy dependence on the older Cuban evidence base.
Notes: Useful only when interpreted against the negative independent trials.
Paper content
This meta-analysis appears positive overall, but its credibility is limited by heavy reliance on the older Cuban evidence base. The pooled estimate is not enough by itself to rescue policosanol, because the best independent replication trials were negative. This is a good example of why pooled numbers need source-context, not just magnitude.
po-SRC-004Systematic review and dose-response meta-analysis of randomized controlled trials.
Sourceopen_in_newGholamrezayi A, Amini MR, Rasaei N, Akhgarjand C, Kalantar Z, Askari G, Hekmatdoost A. What is the influence of policosanol supplementation on liver enzymes? A systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2024;80:103018. doi:10.1016/j.ctim.2024.103018. PMID:38185399.
Population: Adults across 23 randomized controlled trials.
Dose protocol: Dose-response meta-analysis of 23 RCTs (2,535 participants) at various policosanol doses
Key findings: Small significant reductions in ALT (-1.48 U/L) and AST (-1.10 U/L). Most pronounced at 20 mg/day.
Notes: Primarily a safety reassurance data point rather than evidence of therapeutic liver benefit.
Paper content
This dose-response meta-analysis pooled 23 RCTs (2,535 participants) to evaluate policosanol's effect on liver enzymes. Policosanol supplementation produced small but statistically significant reductions in both ALT (-1.48 U/L, P=0.001) and AST (-1.10 U/L, P<0.001). The most pronounced effects occurred at 20 mg/day dosing. While these reductions confirm policosanol does not harm liver function and may produce a marginal hepatoprotective signal, the clinical significance of such small absolute changes is limited. The study is mainly useful as a safety reassurance data point rather than evidence of therapeutic liver benefit.
po-SRC-005Systematic review and dose-response meta-analysis of randomized controlled trials.
Sourceopen_in_newAmini MR, Kazeminejad S, Jalalzadeh M, Sadeghi Majd S, Kavyani Z, Askari G, Hekmatdoost A. The effects of policosanol supplementation on blood glucose: A systematic review and dose-response meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2024;212:111709. doi:10.1016/j.diabres.2024.111709. PMID:38768866.
Population: Adults across 25 randomized controlled trials.
Dose protocol: Dose-response meta-analysis of 25 RCTs (2,680 participants) at various policosanol doses
Key findings: Small significant blood glucose reduction of -2.24 mg/dL. Greatest effects under 24 weeks, in those under 50, and at 10 mg/day.
Notes: Clinically marginal effect size. Minor metabolic data point, not a primary indication.
Paper content
This dose-response meta-analysis pooled 25 RCTs (2,680 participants) to evaluate policosanol's effect on blood glucose. A small but statistically significant reduction of -2.24 mg/dL was found. The greatest effects occurred with treatment under 24 weeks, in individuals younger than 50, and at 10 mg/day. The clinical significance of a 2 mg/dL glucose reduction is marginal, and the authors acknowledged the need for further research. This study adds a data point suggesting policosanol may have minor metabolic effects beyond lipids, but the magnitude is too small to be clinically meaningful on its own.